Text Size
20 studies found for:    EGFRvIII

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
2 Recruiting Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II Clinical Trial.
Condition: Recurrent Glioblastoma
Intervention: Drug: PF-299804 (Dacomitinib)
3 Recruiting White Blood Cells With Anti-EGFR-III for Malignant Gliomas
Conditions: Malignant Glioma;   Glioblastoma;   Brain Cancer
Interventions: Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
4 Recruiting Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
5 Terminated S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Conditions: Brain Tumors;   Gastric Cancer;   Ovarian Cancer;   Prostate Cancer
Interventions: Biological: KLH;   Biological: GMCSF
6 Recruiting AMG 595 First-in-Human in Recurrent Gliomas
Conditions: Advanced Malignant Glioma;   Anaplastic Astrocytomas;   Glioblastoma Multiforme
Intervention: Drug: AMG 595
7 Recruiting Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
Conditions: Brain Cancer;   Brain Stem Tumors;   Pontine Tumors
Intervention: Biological: Rindopepimut
8 Active, not recruiting Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3-KLH conjugate vaccine;   Biological: sargramostim;   Other: placebo
9 Recruiting EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Condition: Brain Cancer
Intervention: Drug: erlotinib
10 Active, not recruiting Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3-KLH conjugate vaccine;   Biological: daclizumab;   Drug: temozolomide;   Other: placebo;   Biological: PEP-3-KLH
11 Terminated Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: erlotinib hydrochloride
12 Active, not recruiting Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
Condition: Malignant Glioma
Interventions: Drug: CDX-110 with GM-CSF;   Drug: temozolomide
13 Terminated Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride;   Drug: isotretinoin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
14 Recruiting Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Erlotinib
15 Recruiting PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Conditions: Head Neck Cancer Squamous Cell Metastatic;   Head Neck Cancer Squamous Cell Recurrent
Intervention: Drug: PF-00299804
16 Recruiting A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
Condition: Esophageal Squamous Cell Carcinoma
Intervention: Drug: PF804
17 Recruiting Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide;   Radiation: radiation therapy
18 Completed
Has Results 		Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
19 Completed Temozolomide and Everolimus in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus;   Drug: temozolomide;   Genetic: microarray analysis;   Other: immunohistochemistry staining method
20 Completed Genistein in Patients Who Are Undergoing Surgery for Bladder Cancer
Condition: Bladder Cancer
Interventions: Dietary Supplement: genistein;   Other: placebo
To Top

† Indicates status has not been verified in more than two years